Federal Register Notice: FDA has determined the regulatory review period for Somatuline Depot is 3,629 days for extending a patent which claims the human drug product. Somatuline Depot (lanreotide), marketed by Tercica, Inc. and manufactured by Ipsen Pharma Biotech, is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. To view this notice, click here.
